Tamoxifen (CAS 10540-29-1) is a high-purity, pharmaceutical-grade SERM (Selective Estrogen Receptor Modulator) synthesized via precision organic synthesis, complying with strict USP and EP quality standards. Its molecular structure is optimized to selectively bind to estrogen receptors, exerting anti-estrogenic effects in breast tissue while maintaining estrogenic activity in bone and cardiovascular systems. Produced with minimal impurities (total impurities ≤0.1%) and rigorous potency verification, each batch ensures consistent therapeutic performance, making it a cornerstone raw material for oncology drug formulation.
This iconic SERM stands out for its proven efficacy in treating hormone receptor-positive breast cancer, reducing tumor growth and recurrence risk in both premenopausal and postmenopausal women. Unlike conventional chemotherapeutics, it targets cancer cells specifically with fewer systemic side effects, and it is also used for breast cancer prevention in high-risk populations. Its dual-action mechanism balances therapeutic efficacy with safety, supporting long-term clinical use and research applications.
Tamoxifen (CAS 10540-29-1) caters to professional needs: pharmaceutical manufacturers developing oncology medications, research institutions studying hormone-related cancer mechanisms, and biotech firms exploring targeted therapies. Its clinical gold-standard status, pharmaceutical-grade purity, and versatile applications make it a top choice for buyers prioritizing reliability and therapeutic value. Whether for large-scale prescription drug production or preclinical research, this SERM meets the stringent demands of the global pharmaceutical and oncology sectors.
